ArticleOncology letters2018
Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review).International journal of molecular medicine · 2026Review
- Erianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway.Scientific reports · 2026Article
- An Updated Review Deciphering the Inhibitory Potential of Erianin via Targeting Several Dysregulated Oncogenes in Several Human Carcinomas.Current pharmaceutical design · 2025Review
- Article
- Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1.Cancer cell international · 2024Article
- Research progress on the regulatory and pharmacological mechanism of chemical components of Dendrobium.Heliyon · 2024Review
- Erianin Impedes the Proliferation and Metastatic Migration Through Suppression of STAT-3 Phosphorylation in Human Esophageal Cancer Cells.Applied biochemistry and biotechnology · 2024Article
- Ferroptosis-Regulated Natural Products and miRNAs and Their Potential Targeting to Ferroptosis and Exosome Biogenesis.International journal of molecular sciences · 2024Review
- Article
- Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review.Frontiers in pharmacology · 2024Review
- Simultaneous determination of phenols in the four main original plants of the famous traditional Chinese medicine Shihu by pressurized capillary electrochromatography.RSC advances · 2023Article
- Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Erianin Induces Ferroptosis of Renal Cancer Stem CellsJournal of Cancer · 2023Article
- The roles of ERIANIN in tumor and innate immunity and its' perspectives in immunotherapy.Frontiers in immunology · 2023Review
- Erianin: A phytoestrogen with therapeutic potential.Frontiers in pharmacology · 2023Review
- Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.Cells · 2022Review
- Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology.Frontiers in molecular biosciences · 2022Article
- The Transcriptome Profiling of Flavonoids and Bibenzyls Reveals Medicinal Importance of Rare OrchidFrontiers in plant science · 2022Article
- The Regulatory Effects and the Signaling Pathways of Natural Bioactive Compounds on Ferroptosis.Foods (Basel, Switzerland) · 2021Review
- Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway.Bioscience reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erianin, a natural bibenzyl compound, is present in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.